Patent ID: 11963980
Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C

Claim 16:
17. The method of claim 16, wherein the CD8+ T cells are engineered to express a chimeric antigen receptor (CAR)-comprising an antigen binding region which binds a tumor associated antigen selected from the group consisting of tEGFR, Her2, CD19, CD20, CD22, mesothelin, tyrosinase, CEA, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, EPHa2, ErbB2, FBP, MAGE-A1, MUC1, NY-ESO-1, and MART-1.